RVTY vs. AVTR, ILMN, BIO, BIO.B, WAT, NBIX, NTRA, BMRN, TECH, and INCY
Should you be buying Revvity stock or one of its competitors? The main competitors of Revvity include Avantor (AVTR), Illumina (ILMN), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Waters (WAT), Neurocrine Biosciences (NBIX), Natera (NTRA), BioMarin Pharmaceutical (BMRN), Bio-Techne (TECH), and Incyte (INCY). These companies are all part of the "medical" sector.
Revvity (NYSE:RVTY) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
In the previous week, Revvity had 2 more articles in the media than Avantor. MarketBeat recorded 11 mentions for Revvity and 9 mentions for Avantor. Avantor's average media sentiment score of 1.10 beat Revvity's score of 0.82 indicating that Avantor is being referred to more favorably in the news media.
86.7% of Revvity shares are held by institutional investors. Comparatively, 95.1% of Avantor shares are held by institutional investors. 0.6% of Revvity shares are held by company insiders. Comparatively, 1.5% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Revvity currently has a consensus price target of $118.17, indicating a potential upside of 9.69%. Avantor has a consensus price target of $26.71, indicating a potential upside of 13.58%. Given Avantor's stronger consensus rating and higher probable upside, analysts plainly believe Avantor is more favorable than Revvity.
Revvity has a net margin of 5.49% compared to Avantor's net margin of 3.79%. Avantor's return on equity of 13.01% beat Revvity's return on equity.
Avantor received 156 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 63.64% of users gave Avantor an outperform vote while only 54.55% of users gave Revvity an outperform vote.
Revvity has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.
Revvity has higher earnings, but lower revenue than Avantor. Avantor is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.
Summary
Avantor beats Revvity on 12 of the 18 factors compared between the two stocks.
Get Revvity News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
